Swedbank AB Grows Holdings in Eli Lilly and Company $LLY

Swedbank AB boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 17.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,553,263 shares of the company’s stock after buying an additional 231,334 shares during the period. Eli Lilly and Company makes up approximately 1.2% of Swedbank AB’s holdings, making the stock its 10th largest holding. Swedbank AB owned approximately 0.16% of Eli Lilly and Company worth $1,185,140,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Wealth Preservation Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 1st quarter worth about $27,000. Sumitomo Mitsui Financial Group Inc. bought a new stake in Eli Lilly and Company in the second quarter worth about $27,000. Evolution Wealth Management Inc. bought a new stake in Eli Lilly and Company in the second quarter worth about $29,000. Steph & Co. boosted its position in shares of Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after buying an additional 29 shares during the period. Finally, Financial Gravity Companies Inc. bought a new position in shares of Eli Lilly and Company during the second quarter valued at approximately $31,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $1,077.06 on Friday. The firm has a market cap of $1.02 trillion, a P/E ratio of 52.69, a P/E/G ratio of 1.09 and a beta of 0.37. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99. The stock’s fifty day moving average price is $981.27 and its 200-day moving average price is $839.03.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same period in the prior year, the firm earned $1.18 earnings per share. The firm’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s payout ratio is 29.35%.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on LLY shares. The Goldman Sachs Group raised their price target on Eli Lilly and Company from $951.00 to $1,145.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. UBS Group reiterated a “neutral” rating on shares of Eli Lilly and Company in a research report on Thursday, December 18th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Wells Fargo & Company raised their price target on shares of Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Four investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,155.36.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.